**To the Editor:** We report the first isolation of a multiple antimicrobial drug--resistant strain of Shiga toxin--producing *Escherichia coli* (STEC) O118:H16 from cattle in Latin America. The strain was isolated during a study of fecal STEC in 205 healthy and 139 diarrheic cattle on 12 beef farms in the state of São Paulo, Brazil, in February 2000; one case of STEC was found in a 1-month-old calf with diarrhea. This bovine STEC O118:H16 strain showed resistance to eight antimicrobial substances; the following resistance (R)-genes were detected: ampicillin (*bla*~TEM1-like~), kanamycin and neomycin (*aphA1*), streptomycin (*strA/B*), sulphametoxazol (*sul2*), tetracyclin (*tet*\[A\]), trimethoprim (no *dfrA1,* *A5*, *A7*, *A12*, *A14*, or *A17*), and trimethoprim/sulphamethoxazol. The STEC O118:H16 strain from Brazil was found to be similar for virulence genes (Shiga toxin 1 \[*stx*1\], intimin beta 1 \[*eae* β1\], and EHEC-hemolysin \[E-*hly*A\]) and for antimicrobial drug resistance to STEC O118:H16 strains, which were isolated in different countries of Europe ([@R1]). Beginning in 1986, STEC O118:H16 was identified as an emerging pathogen for calves and humans in Belgium and Germany ([@R2]--[@R4]). Cattle and human STEC O118:H16 isolates were similar in virulence attributes and antimicrobial drug resistance and belonged to a distinct genetic clone ([@R1]). Transmission of these pathogens from cattle to humans on farms was observed ([@R5]).

Beginning in 1996, STEC O118:H16 has become important as an emerging pathogen in humans and has been associated with bloody diarrhea and hemolytic uremic syndrome ([@R2]). Analysis of the antimicrobial resistance profiles showed that \>96% of the European STEC O118:H16 strains showed resistance to one or more antimicrobial drugs in contrast to the 10% to 15% drug-resistant strains that were detected among STEC belonging to other serotypes ([@R1],[@R6],[@R7]). STEC O118:H16 showing multiresistance in up to eight different antimicrobial drugs predominated among younger isolates, indicating that drug resistance genes have accumulated over time in STEC O118:H16 strains. The frequency of antimicrobial drug resistance in STEC and Stx-negative *E. coli* in humans and animals was compared in a study by Schroeder et al. ([@R8]). Among human clinical *E. coli* isolates, antimicrobial resistance was less frequently observed in STEC than in Stx-negative strains, whereas in cattle, antibiotic-resistant strains were found at similar frequencies in both groups of *E. coli*. The relatively higher frequency of antimicrobial-resistant STEC in cattle was explained by the use of antimicrobial drugs in cattle production, whereas human infections with STEC are generally not treated with antibiotics ([@R8]). Cattle could thus be an important source of new emerging antibiotic-resistant STEC strains such as O118:H16.

The genetic basis of antimicrobial resistance in STEC O118:H16 is broad, including R-plasmids, integrons, transposons, and chromosomally inherited drug-resistance genes. Fluoroquinolone resistance has also been acquired by some STEC O118:H16 strains ([@R1]). The heterogenicity of antimicrobial drug--resistance patterns, the increase of multidrug-resistant strains over time of isolation, and the evidence for multiple aquisition and genetic location of R-determinants indicate that strains belonging to the STEC O118:H16 clone have a propensity to acquire and accumulate R-genes. The finding that multidrug-resistant STEC O118:H16 is isolated from cattle in South America indicates the global spread of this new emerging EHEC type.
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